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Abstract
A systematic characterization of the composition and structure of the bacterial cell-surface proteome 
and its complexes can provide an invaluable tool for its comprehensive understanding. 
The knowledge of protein complexes composition and structure could oﬀer new, more eﬀective targets 
for a more speciﬁc and consequently eﬀective immune response against a complex instead of a single 
protein.
Large-scale protein-protein interaction screens are the ﬁrst step towards the identiﬁcation of complexes 
and their attribution to speciﬁc pathways. Currently, several methods exist for identifying protein 
interactions and protein microarrays provide the most appealing alternative to existing techniques for a 
high throughput screening of protein-protein interactions in vitro under reasonably straightforward 
conditions. 
In this study approximately 100 proteins of Group A Streptococcus (GAS) predicted to be secreted or 
surface exposed by genomic and proteomic approaches were puriﬁed in a His-tagged form and used to 
generate protein microarrays on nitrocellulose-coated slides. To identify protein-protein interactions 
each puriﬁed protein was then labeled with biotin, hybridized to the microarray and interactions were 
detected with Cy3-labelled streptavidin. Only reciprocal interactions, i. e. binding of the same two 
interactors irrespective of which of the two partners is in solid-phase or in solution, were taken as bona 
ﬁde protein-protein interactions. Using this approach, we have identiﬁed 20 interactors of one of the 
potent toxins secreted by GAS and known as superantigens. Several of these interactors belong to the 
molecular chaperone or protein folding catalyst families and presumably are involved in the secretion 
and folding of the superantigen. In addition, a very interesting interaction was found between the 
superantigen and the substrate binding subunit of a well characterized ABC transporter. This ﬁnding 
opens a new perspective on the current understanding of how superantigens are modiﬁed by the 
bacterial cell in order to become major players in causing disease. 
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1. Introduction
1.1 Streptococcus pyogenes
Group A streptococcus (GAS) or Streptococcus pyogenes is a Gram-positive, non-motile, 
non-spore forming coccus. It divides in one plane and this it forms pairs of cells or 
(especially in liquid media) chains of various length (Figure 1.1). The bacterial cell is 
mostly round to ovoid, about 0.6 to 1.0 micrometer in diameter. S. pyogenes is a catalase-
negative aero-tolerant anaerobe (facultative anaerobe) organism with fermentative 
metabolism and requires enriched medium containing blood in order to grow. Group A 
streptococci typically have a capsule composed of hyaluronic acid and exhibit beta (clear) 
hemolysis on blood agar (Wannamaker 1970). 
GAS is a common pathogen of humans, present usually in the respiratory tract in 5 to 
15% of normal individuals without signs of disease. As part of the normal ﬂora, if 
defenses are compromised or when the organisms are able to penetrate the constitutive 
defenses S. pyogenes can generate a variety of suppurative infections.
GAS has been the main cause of puerperal fever (sepsis after childbirth) and scarlet fever 
in the last century, but now, due to antibiotic treatment, is mostly known for causing 
streptococcal pharyngitis whereas severe complications such as erysipelas (a form of 
cellulitis accompanied by fever and systemic toxicity) have become less common. 
Recently however the severity and sequelae of GAS infections have increased and severe 
invasive streptococcal infections lead to the deﬁnition of S. pyogenes as the "ﬂesh eating 
bacteria" in the news media (Wannamaker 1970). 
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Today GAS remains a major worldwide 
health concern in cases involving rapidly 
progressive disease and serious sequelae of 
untreated infections and eﬀorts are directed 
toward a better characterization of infection 
mechanisms and identifying rheumatogenic 
and nephritogenic strains of streptococci. 
Today’s acute GAS infections are mainly 
pharyngitis (strep throat), scarlet fever (rash), 
impetigo (superﬁcial skin layers infection) or 
cellulitis (deep skin layers infection) but, 
when the pathogen becomes invasive, 
sequelae can result in necrotizing fasciitis, 
myositis and streptococcal toxic shock 
syndrome. Following acute infections also 
immune-mediated sequelae may occur such 
as acute rheumatic fever and acute 
glomerulonephritis.
GAS produces in a very large number of 
diseases and a wide array of virulence factors 
including: (1) M protein, ﬁbronectin-binding 
protein (Protein F) and lipoteichoic acid for 
adherence; (2) hyaluronic acid capsule as an 
immunological disguise and to inhibit 
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Figure 1.1. Electron micrograph of an ultra-thin 
section of a chain of group A streptococci (20,000X). 
The cell surface ﬁbrils, consisting primarily of M 
protein, are clearly evident. The bacterial cell wall, to 
which the ﬁbrils are attached. Incipient cell division is 
also indicated by the nascent septum formation near 
the cell equator. The streptococcal cell diameter is 
equal to approximately one micron. 
Electron micrograph of Streptococcus pyogenes by 
Maria Fazio and Vincent A. Fischetti, Ph.D., 
Laboratory of Bacter ia l Pathogenesis and 
Immunology, Rockefeller University. 
phagocytosis; M-protein to inhibit phagocytosis (3) invasins such as streptokinase, 
streptodornase (DNAse B), hyaluronidase, and streptolysins; (4) exotoxins, such as 
pyrogenic (erythrogenic) toxin which causes the rash of scarlet fever and systemic toxic 
shock syndrome. 
1.1.2 Classiﬁcation of Streptococci 
Streptococci have long been classiﬁed by hemolytic reaction type displayed on blood agar: 
alpha-hemolysis is a partial hemolysis resulting in reduction of red cell hemoglobin, 
whereas beta-hemolysis results in complete red cell lysis in the colony surroundings 
(Figure 1.2). Non hemolytic type is deﬁned gamma-hemolytic. Group A streptococci are 
mostly beta-hemolytic whereas for example Group B streptococci can generate alpha, 
beta or gamma hemolysis. Most of the oral streptococci are non hemolytic making 
hemolysis not a very reliable tool for absolute identiﬁcation, but it is still widely used for 
rapid screens for identiﬁcation of S. pyogenes. 
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Figure 1.2. Streptococcus pyogenes. Left: Gram stain of S. pyogenes in a clinical specimen. Right: 
Colonies of S. pyogenes on blood agar exhibiting beta (clear) hemolysis (Todar 2008).
Historically, the deﬁnitive identiﬁcation of streptococci has rested on the serologic 
reactivity of "cell wall" polysaccharide antigens as originally described by Rebecca 
Lanceﬁeld (Lanceﬁeld 1933). Eighteen group-speciﬁc antigens (Lanceﬁeld groups) were 
established. The Group A polysaccharide is a polymer of N-acetylglucosamine and 
rhamnose. Some group antigens are shared by more than one species. This polysaccharide 
is also called the C substance or group carbohydrate antigen.
1.1.3 Pathogenesis
Streptococcus pyogenes successfully colonizes and rapidly multiplies, spreading while 
evading phagocytosis and confusing the immune system. The respiratory tract, 
bloodstream, or the skin are targets for acute diseases but Streptococcal disease is most 
often a respiratory (pharyngitis or tonsillitis) or skin (pyoderma) infection (Bisno and 
Stevens 1996). 
S. pyogenes remains the leading cause of bacterial pharyngitis and tonsillitis (strep throat) 
causing also other infections such as otitis, sinusitis, and pneumonia and skin infections: 
noninvasive (impetigo) or invasive (cellulitis). Deep GAS infections may reach joint or 
bone infections and cause also necrotizing fasciitis, myositis, meningitis and endocarditis. 
Rheumatic fever and glomerulonephritis, two post streptococcal sequelae, occur in 1-3% 
of untreated infections following streptococcal disease (Bisno 1991). 
These pathologies are caused by immunological reactions to GAS antigens where 
circulating streptococcal toxins trigger systemic responses that result in scarlet fever and 
streptococcal toxic shock syndrome. Many GAS virulence factors are present on the 
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bacterial cell surface, and of particular interest are those involved in colonization and 
evasion of the host immune responses (Kaplan 1991). Group A Streptococcus has a 
highly complex and diverse cell surface, rich of antigenic components such as the capsule 
polysaccharide (C-substance), the cell wall peptidoglycan and many surface proteins 
including the M protein, ﬁmbrial and ﬁbronectin-binding proteins. A few antigens 
mimic molecularly human tissue of the skeleton, smooth muscle, heart and nervous 
system to avoid host immune response causing autoimmune sequelae.
In Group A streptococci, also the carbohydrate group (N-acetylglucosamine and 
rhamnose) wasn’t thought to be antigenic, but emerging highly invasive strains present 
mucoid colonies. This suggests a role of the capsule in virulence.
1.1.4 GAS surface
M Protein
Major virulence factor involved in colonization and phagocytosis resistance is the M 
proteins class. This protein class is the primary cause of the high antigenic variability of 
GAS resulting in more than 100 serotypes of Group A Streptococcus identiﬁed based on 
M proteins antigenic speciﬁcity.
The M proteins are able to bind serum ﬁbrinogen allowing the bacteria to resist 
phagocytosis and contain those particular epitopes that mimic human tissues some of 
these are the cause of rheumatic fever, leading to an autoimmune carditis. 
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The Capsule
Even though non antigenic, the capsule of S. pyogenes, because of its hyaluronic acid 
composition (chemically similar to host connective tissue), allows the bacterium to hide 
from the host immune system preventing neutrophils and macrophages phagocytosis.
Adhesins
Group A Streptococcus is known (as other pathogens) to produce adhesins with diﬀerent 
speciﬁcities. GAS adhesins identiﬁcation have long been subject of conﬂict and debate 
but it is believed that they participate in bacterial adherence to host epithelial cells. M 
protein itself is part of this group (Caparon, Stephens et al. 1991) as well as some 
ﬁbronectin-binding proteins (that mediate streptococcal adherence to the amino 
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Figure 1.3. Cell surface structure of Streptococcus pyogenes and secreted products involved 
in virulence.
terminus of ﬁbronectin on mucosal surfaces) and lipoteichoic acids (LTA) anchored to 
proteins on the bacterial surface (including the M protein) (Hasty, Ofek et al. 1992). 
Invasins and Exotoxins
During colonization of the upper respiratory tract and acute pharyngitis GAS may spread 
to other portions of the upper or lower respiratory tracts resulting in infections of the 
middle ear (otitis), sinuses (sinusitis) or lungs (pneumonia). If untreated, the infection 
may extends to the meninges (meningitis) as well as bones (osteomyelitis) or joints 
(arthritis). During these aspects of acute disease streptococci express a variety of secretory 
proteins that mediate the invasion, interacting with host blood and tissue components, 
killing cells and inducing a damaging inﬂammatory response. 
Among the major proteins involved in this phase such as GAS toxins and a part of the 
soluble extracellular growth products, there are Streptolysin S, an oxygen-stable 
leukocidin; Streptolysin O, an oxygen-labile leukocidin; NADase, leukotoxic; 
Hyaluronidase, known as “the spreading factor”, which can digest hyaluronic acid of 
connective tissue; Streptokinases, that participate in ﬁbrin lysis; Streptodornases A-D, 
characterized by deoxyribonuclease activity and Streptodornases B and D, with a 
ribonuclease activity.
This large repertoire of products is important in the pathogenesis of S. pyogenes infections. 
Streptococcal invasins act in a variety of ways lysing red blood cells, phagocytes and other 
host macromolecules as they allow the bacteria to spread among tissues. Invasins are key 
proteins in GAS pathogenesis and the eﬀects of antibodies against these proteins resulted 
in relatively insigniﬁcant host protection.
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1.1.5 Streptococcal Superantigens: Pyrogenic Exotoxins
An interesting role in this study is played by a particular type of toxin belonging to the 
superantigen (SAgs) class. During the late 1980s some unexpected immunological 
properties were discovered and attributed to the highly mitogenic staphylococcal 
enterotoxins (SEs) on T lymphocytes: the triggering of lymphocyte proliferation by SEs 
requires selective and simultaneous binding of these molecules by both major 
histocompatibility complex (MHC) class II molecules at the surface of accessory cells and 
T cell receptors (TcR) on target lymphocytes. This confers SEs the properties of 
functionally bivalent molecules by cross-linking TcR and MHC class II molecules in a 
unique manner. Dependence on class II molecules was not due to an immunological 
“recognition” of SEs (as is commonly known for conventional antigens) since they 
stimulate T cells by binding class II MHC molecules directly and nonspeciﬁcally (Figure 
1.4) so that about 20% of T cells may be stimulated (whereas 1 every 10.000 T cells are 
stimulated by conventional antigens) resulting in massive cytokine release. 
To date the constantly expanding literature describes at least 40 bacterial SAgs produced 
by Gram-positive bacteria like Staphylococcus aureus, Streptococcus pyogenes (and other 
species), as well as those produced by Gram-negative bacteria such as Yersinia 
pseudotuberculosis and the wall-less Mycoplasma arthritidis.
The repertoire of S. pyogenes SAgs includes 11 structurally and functionally related single-
chain proteins with molecular weights ranging from about 23 to 27 kDa (Alouf and 
Muller-Alouf 2003; Petersson, Forsberg et al. 2004). Most of these proteins have been 
puriﬁed to homogeneity including the classical erythrogenic (scarlet fever) toxins A and 
C, also designated streptococcal pyrogenic exotoxins A and C (SPE A, SPE C) identiﬁed 
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in 1924 and 1960 respectively(Alouf 1980; Norgren 1997; Alouf 1999; Alouf and 
Muller-Alouf 2003). SPE A (25,787 Da) and SPE C (24,354 Da) are respectively 
encoded by bacteriophage genes speA and speC; and a series of recently discovered 
mitogenic exoproteins, namely streptococcal superantigen (SSA) (Mollick, Miller et al. 
1993), SMEZ (streptococcal mitogenic exotoxin Z) isolated by Kamezawa and colleagues 
(Kamezawa, Nakahara et al. 1997), SPE G, SPE H, SPE I, SPE J (Proft, Moﬀatt et al. 
1999; Proft, Moﬀatt et al. 2000; McCormick, Pragman et al. 2001), SPE L, and SPE M 
(Smoot, McCormick et al. 2002; Proft 2003).
The occurrence of some of these exotoxins discovered over the past twelve years was 
initially inferred by genome mapping of S. pyogenes serotypes M1, M3, and M18 
(Ferretti, McShan et al. 2001; Beres, Sylva et al. 2002; Smoot, Barbian et al. 2002). The 
respective genes were further transcribed and the superantigenicity, as well as lethality of 
corresponding SAg proteins, established experimentally (Smoot, McCormick et al. 2002). 
Serologic studies showed the presence of antibodies against these SAgs in patients (Proft 
2003). All known streptococcal SAgs with the exception of SMEZ, SPE G, and SPE J are 
encoded by bacteriophage genes integrated into the bacterial chromosome (Ferretti, 
McShan et al. 2001; Proft, Sriskandan et al. 2003). Four naturally occurring speA alleles 
have been found in strains recovered from patients with severe invasive diseases. 
Determination of the nucleotide sequences from the eleven streptococcal SAgs identiﬁed 
to date has revealed various degrees of structural relatedness at both the amino acid 
sequence and three-dimensional levels. These SAgs share important structural homologies 
with various S. aureus enterotoxin SAgs. Interestingly, certain streptococcal SAgs are more 
similar to some staphylococcal SAgs than to other streptococcal SAgs. The genomic and 
structural relatedness suggests that these SAgs share a common ancestor (Arcus, Proft et 
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al. 2000; Sundberg, Li et al. 2002). Other streptococcal superantigens, SPE M, SSA, and 
SME Z have been identiﬁed from invasive strains of group C and G Streptococcus 
dysgalactiae. 
The molecular structure, the genetic aspects and the interaction of these fascinating 
molecules with the immune system remains their most interesting aspects. The key role of 
SAgs in the pathogenesis of acute, chronic, and some autoimmune diseases has oﬀered 
new insights into elucidating patho-physiological eﬀects of these molecules. Many 
questions remain unanswered, but new achievements will certainly emerge in the coming 
years, such as the design and use of novel therapeutical strategies (drugs and vaccines) in 
the management of SAgs-induced diseases.
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Figure 1.4. Representation of T cell activation by a conventional peptide antigen (Ag) or 
by a superantigenic toxin (SAg). TcR: T cell receptor; APC: antigen-presenting cell; 
MHC II: major histocompatibility class II complex molecule (Alouf 1999).
1.2 S. Pyogenes secretome: The ExPortal
Recent studies (Buist, Ridder et al. 2006) on secretions system types in Gram-positive 
bacteria describe how they may employ unique strategies to ensure proper folding of the 
prodigious quantities of proteins these organisms typically secrete. In the past two years 
three papers appeared that demonstrated the localization of components of the Sec 
pathway in the pathogen Streptococcus pyogenes. Immunogold electron microscopy 
analysis of thin sections of S. pyogenes showed that a microdomain with a high 
concentration of Sec translocons called the ExPortal is present in this coccoid bacterium 
(Rosch and Caparon 2004). In particular, for example, the secreted cysteine protease 
SpeB, its maturation protein HtrA and the heterologous alkaline phosphatase PhoZ all 
co-localize with SecA in this domain (Rosch and Caparon 2004; Rosch and Caparon 
2005).
The ExPortal (Figure 1.5) is proposed to function as an organelle that promotes 
biogenesis of secreted proteins by coordinating interactions between nascent unfolded 
secretory proteins and membrane-associated chaperones.
The surface localization of the covalently cell-wall-bound M protein of S. pyogenes and the 
way it ﬁts in this mechanism remains to be explained. Although a single microdomain for 
protein secretion was identiﬁed in this bacterium, the M protein is present on the whole 
cell surface. How the distribution of this protein is directed remains to be elucidated.
These ﬁndings are conﬁrmed by a recent localization study of Sortase A in S. pyogenes 
(Raz and Fischetti 2008). Cell wall peptidoglycan-anchored surface proteins are essential 
virulence factors in many gram-positive bacteria. The attachment of these proteins to the 
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peptidoglycan is achieved through a transpeptidation reaction, whereby sortase cleaves a 
conserved C-terminal LPXTG motif and covalently attaches the protein to the 
peptidoglycan precursor lipid II.
The LPXTG sequence presenting proteins are of particular interest as potential vaccine 
candidates for their localization on the outer membrane and consequently they are part 
of this study on surface protein complexes.
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Figure 1.5. Graphical representation of the protein localization patterns in diﬀerent bacteria and 
especially in S. Pyogenes  (Buist, Ridder et al. 2006).
1.3 Vaccine against Group A Streptococcus
In the past decades many genomes of several microorganisms have been sequenced and 
sequence analysis improved considerably developing invaluable tools for pharmaceutical 
research. In silico prediction of structure and function of proteins starting from the 
genome sequence has become more accurate changing the approach for drug discovery 
and especially the development of a vaccine.   
1.3.1 Reverse Vaccinology
In 2000 Rappuoli and colleagues published the Reverse Vaccinology approach for vaccine 
development using recombinant proteins (Rappuoli 2000). Until then the study for a 
new vaccine started from the microorganism and its exposed factors focusing towards 
identifying the DNA and its characterization. Reverse vaccinology ﬁrst step is “the 
genome” (Masignani, Rappuoli et al. 2002). Looking into the gene sequences it’s possible 
to identify all the pathogen proteins and among them the potential antigenic candidates 
starting with those whose sequence hint surface exposure or secretion (Rappuoli and 
Covacci 2003). This process is not dependent on single proteins properties or the 
pathogen characteristics (Mora, Veggi et al. 2003).
Conventional vaccines are obtained from attenuated live pathogens, inactivated ones or 
subunits able to confer protection. Reverse vaccinology screening for protective antigens 
that started in silico is continued both in vitro and in vivo. Once identiﬁed, genes coding 
for pathogen proteins are cloned in E. coli, expressed and puriﬁed. Puriﬁed proteins are 
13
Vaccine
development
Clone genes
Antigen selection
Test 
convalescent 
sera
Test 
immunogenicity
Immunogenicity testing 
in animal models
Identify
components
Purify 
components
5–15 
years
1–2 
years
Vaccine
Start from the whole genomic sequence
Computer 
prediction
In silico 
vaccine candidates
Express 
recombinant proteins
DNA vaccine
preparation*
Conventional vaccine development
Reverse vaccinology
a
b
14
Figure 1.6. Approaches to vaccine development. Schematic demonstration of the essential steps required for vaccine 
development using the conventional approach (a), and reverse vaccinology (b) (Johri, Paoletti et al. 2006).
used to immunize mice and obtain sera, that once tested, are used to verify the predicted 
exposure and the ability to trigger an immune response. Protective antigens are analyzed 
again in vitro with opsonophagocytosis and bactericidal assays focused towards ﬁnal 
antigen selection. Interesting candidates are also analyzed for sequence conservation 
among diﬀerent pathogen strains.
Reverse Vaccinology, schematized in ﬁgure 1.6, is able to succeed where traditional 
methodology fails (e.g. non-culturable or highly infective pathogens) and also to improve 
existing products.
1.3.2 The Novartis Approach
Reverse Vaccinology pointed out how antigens that confers a broad range of protective 
antibody responses are highly expressed surface exposed components, usually secreted 
toxins or virulence factors well conserved among the pathogen strains. The search for 
protective antigen can last, however, even years: time is the main limitation of this 
methodology and the biological assay for candidates identiﬁcation is a huge bottle-neck. 
For Group A Streptococcus vaccine study, Reverse Vaccinology has been integrated with 
proteomic analysis of GAS cell surface and both DNA and protein microarray screening 
of GAS-infected patient sera. 
The proteomic approach was used to identify bacterial surface-exposed proteins for their 
use as vaccine candidates. To achieve this whole cells are treated with proteases to 
selectively digest protruding proteins that are subsequently identiﬁed by mass 
spectrometry analysis of the released peptides. Applying this approach to GAS 
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M1_SF370 strain, resulted in 68 PSORT-predicted surface-associated proteins identiﬁed 
on its surface (Figure 1.7), including most of the protective antigens described in the 
literature. Diﬀerent capsule content inﬂuence the number of identiﬁed surface-exposed 
proteins which varies from strain to strain. This strategy overcomes the diﬃculties so far 
encountered in surface protein characterization and has great potential in vaccine 
discovery (Musser 2006).
As part of the high throughput approach for vaccine studies, both DNA and protein 
Microarray technology have been used while screening for protective antigens. Among 
the other applications of this technology such as comparative genomic hybridization or 
detection of SNPs, DNA microarray are used for gene expression proﬁling, revealing the 
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Figure 1.7. Strategy used to identify a new mouse-protective group A Streptococcus antigen. Bacteria 
are treated with trypsin to release surface-exposed peptides, which are subsequently identiﬁed by mass 
spectrometry. Genes encoding these proteins are cloned, and the overexpressed proteins are puriﬁed 
and used to immunize mice. The immunized animals are challenged with virulent group A 
Streptococcus to test for protection (Musser 2006).
most expressed genes. This technique requires the whole genome to be spotted on a 
microarray chip (usually glass or silicone) of DNA oligonucleotides, each containing 
picomoles of a speciﬁc DNA sequence such as a short section of a gene or other DNA 
element that are used to hybridize ﬂuorophore-labeled mRNA probes under high-
stringency conditions. Probe-target hybridization is detected and ﬂuorescence is 
quantiﬁed to determine relative abundance of nucleic acid sequences. 
In the study of a vaccine against GAS, microarray technology showed valuable screening 
potentials. Microarrays weren’t only implemented for gene proﬁling on DNA chips, but 
also for identiﬁcation of most immunogenic antigens, proﬁling of disease-speciﬁc 
antibody response and, what this work focuses on, for the analysis of protein-protein 
interactions to identify surface protein complexes. Several protein chips were spotted with 
pools of proteins both predicted by computational analysis to be exposed or secreted and 
veriﬁed by FACS and surfome analysis (Rodriguez-Ortega, Norais et al. 2006). These 
proteins were also screened against sera of patient infected with Group A Streptococcus. 
Similarly to DNA microarray but with human antibodies as probes several hybridization 
experiment were performed and binding detected with ﬂuorophore labeled secondary 
antibodies. 
These data, combined with surfome analysis and Reverse Vaccinology approach narrow 
the potential candidate to an even smaller array of antigens that undergo high 
throughput expression and puriﬁcation and are used in vitro and in vivo assays to select 
the ﬁnal vaccine candidates.
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1.4 Protein Microarrays
Microarray technology allows the simultaneous analysis of many parameters within a 
single experiment (Figure 1.8). Molecules are immobilized in a grid of micro-spots onto a 
solid support and exposed to samples containing the corresponding binding molecules. 
Readout systems based on diﬀerent techniques such as ﬂuorescence, chemiluminescence 
or radioactivity can be used to detect complex formation within each spot. Recent 
18
Figure 1.8. Microarrays for genomics and proteomics. The physiological state of a cell is inﬂuenced by 
external and internal parameters. Microarray technology can be applied to monitor intracellular gene 
and protein expression mechanisms. DNA microarrays are used for genetic analysis as well as expression 
analysis at the mRNA level. Protein microarrays are used for expression analysis at the protein level and 
in the expansive ﬁeld of interaction analysis (Templin, Stoll et al. 2002).
developments in the ﬁeld of protein microarrays show applications for enzyme–substrate, 
DNA–protein and diﬀerent types of protein–protein interactions (Templin, Stoll et al. 
2002). 
The fundamental principles of miniaturized micro-spot ligand-binding assays were 
described more than a decade ago. In the “ambient analyte theory” Roger Ekins and 
coworkers (Ekins 1989; Ekins, Chu et al. 1990; Ekins and Chu 1992) explained why 
microspot assays are more sensitive than any other ligand-binding assay. At that time, the 
high sensitivity and enormous potential of micro-spot technology had already been 
demonstrated using miniaturized immunological assay systems. The possibility of 
determining thousands of diﬀerent binding events in one reaction in a parallel fashion 
perfectly suited the needs of genomic approaches in biology. The rapid progress in whole-
genome sequencing (Lander, Linton et al. 2001; Venter, Adams et al. 2001) and the 
increasing importance of expression studies was matched with eﬃcient in vitro techniques 
for synthesizing speciﬁc capture molecules for ligand-binding assays. New trends in 
technology, mainly in microtechnology and microﬂuidics, newly established detection 
systems and improvements in computer technology and bioinformatics were rapidly 
integrated into the development of microarray-based assay systems. Now, microarrays, 
built from tens of thousands of diﬀerent probes per square centimeter, are well-
established high-throughput hybridization systems that generate huge sets of data within 
a single experiment.
In principle, any type of ligand-binding assay that relies on the product formation of an 
immobilized capture molecule and a target (binder or analyte) present in the surrounding 
solution can be miniaturized, parallelized and performed in a microarray format (Figure 
1.9). Microarray-based assays using nucleic acid–nucleic acid interactions (DNA chips) 
19
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Figure 1.9. Classes of capture molecules for protein microarrays. For speciﬁc interaction analysis, diﬀerent 
classes of molecules can be immobilized on a planar surface to act as capture molecules in a microarray assay. 
(a)Illustrates antigen–antibody interaction and (b) shows a scheme of a Sandwich immunoassay. In (c), a 
speciﬁc protein–protein interaction is shown. A diﬀerent class of binders is shown in (d), where synthetic 
molecules referred to as aptamers act as capture molecules. They can be composed of nucleotides, 
ribonucleotides or peptides. Interactions of enzymes with their speciﬁc substrates are shown in (e), where a 
substrate (S) for kinases is immobilized and phosphorylated (P) by the respective kinase. A typical example 
for a receptor–ligand interaction is given in (f), where synthetic low molecular mass compounds are 
immobilized as capture molecules (Templin, Stoll et al. 2002).
are well established and protein microarray assays are just becoming popular. Studies on 
DNA–protein interactions in a microarray format were performed by Bulyk and 
colleagues (Bulyk, Gentalen et al. 1999) who created microarrays of double-stranded 
oligonucleotides. High-density microarrays of single-stranded oligonucleotides were 
produced using Aﬀymetrix (Santa Clara, CA, USA) technology. In general, DNA–
protein interaction assays could be useful for the characterization and identiﬁcation of 
DNA-binding proteins, such as transcription factors. Enzyme–substrate arrays have been 
described for diﬀerent kinds of enzymes, such as restriction enzymes, peroxidase, 
phosphatase and protein kinases (Bulyk, Gentalen et al. 1999; Arenkov, Kukhtin et al. 
2000; MacBeath and Schreiber 2000; Zhu, Klemic et al. 2000). In a proof of concept 
experiment, MacBeath and Schreiber (MacBeath and Schreiber 2000) immobilized three 
diﬀerent kinase substrates, each speciﬁc for an individual kinase, onto a planar glass 
surface. Using this approach, novel activities of individual kinases were identiﬁed. 
Sequence comparison of enzymes that could phosphorylate tyrosine residues revealed that 
they often share common amino acid residues around their catalytic region. For receptor–
ligand assays, small organic molecules produced by combinatorial solid phase chemistry 
were immobilized in a microarray format. These microarrays produced by so-called small-
molecule printing technology were incubated with ﬂuorescently labeled target proteins to 
identify new ligands (MacBeath and Schreiber 2000). This technology enables parallel 
high-throughput screening for ligand–receptor interactions at very low sample 
consumption, which could improve screening for active substances in the pharmaceutical 
industry.
In the ﬁeld of protein–protein interaction assays, dot-blot ﬁlter arrays were used to screen 
for speciﬁc interactions of immobilized proteins with other proteins (Figure 1.10). 
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Speciﬁc protein–protein interactions were detected between a radioactively labeled 
human p52 GST fusion protein and immobilized capture proteins such as nucleoline or a 
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Figure 1.10. Protein Microarray. Binding of diﬀerent proteins can be detected with a microarray-based assay. 
Speciﬁc capture proteins or antibodies immobilized in an array interact with their respective target proteins 
present in the solution and then labeled with ﬂuorochromes. The resulting signal intensity correlates with  the 
amount of captured target. Within each microarray, diﬀerent  kinds of control spots can be included, such as 
positive and negative  control spots and/or internal calibration spots. This will allow accurate signal quantiﬁcation 
(Templin, Stoll et al. 2002).
serine–arginine protein fraction isolated from HeLa cells (Ge 2000). In addition, 
interactions of DNA, RNA, or low molecular weight ligands with the immobilized 
molecules were shown. Such arrays could be further miniaturized and therefore have the 
potential to be performed in a microarray format.
Zhu et al. (Zhu, Bilgin et al. 2001) demonstrated the extraordinary power of array-based 
methods for proteomic approaches. After puriﬁcation of 5800 diﬀerent recombinant 
proteins from S. cerevisiae, the authors generated complex proteome chips that contained 
gene-products from >90% of the genes of the organism. These microarrays could be used 
to study protein–protein interactions on a genome-wide scale. Using calmodulin as a 
model protein to probe the arrays, many known interactions could be conﬁrmed and a 
set of novel binding proteins was detected. Inspection of the sequences of these proteins 
revealed the presence a binding motif and therefore strongly argues for the signiﬁcance of 
the observed binding interaction. Experiments designed to detect protein–lipid 
interactions showed that the identiﬁcation of proteins able to bind low molecular weight 
compounds is possible. This opens the possibility to examine an entire proteome directly 
for protein–drug interactions.
Microarray immunoassays are of general interest also for all diagnostic applications where 
several parameters of one sample have to be analyzed in parallel (Mendoza, McQuary et 
al. 1999; Joos, Schrenk et al. 2000; Schweitzer, Wiltshire et al. 2000).
Accurate quantiﬁcation with protein microarrays can be achieved by including positive 
and negative control spots and/or internal calibration spots. This will ﬁnally lead to 
robust and reliable diagnostic assays.
Protein microarray technology is already a useful tool to study diﬀerent kinds of protein 
interactions. Further developments and optimization of array production and assay 
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performance combined with high-throughput generation of protein targets and ligands 
will extend the number of applications of protein microarrays dramatically. Proteomic 
research and diagnostic applications will be the two major ﬁelds addressed by protein 
microarray technologies.
In medical research, protein microarrays will accelerate immune diagnostics signiﬁcantly 
by analyzing in parallel all relevant diagnostic parameters of interest. The reduction of 
sample volume is of great importance for all applications in which only minimal amounts 
of samples are available. One example might be the analysis of multiple tumor markers 
from a minimum amount of biopsy material. Furthermore, new possibilities for patient 
monitoring during disease treatment and therapy will be developed based on this 
emerging technology. Microarray-based technology beyond DNA chips will accelerate 
basic research in the area of protein–protein interactions and will allow protein proﬁling 
from limited numbers of proteins up to high density array-based proteomic approaches. 
Protein and peptide arrays will be used to analyze enzyme–substrate speciﬁcity and for 
measurement of enzyme activity on diﬀerent kinds of substrates in a highly parallel 
fashion (Templin, Stoll et al. 2002).
The whole ﬁeld of protein microarray technology shows a dynamic development driven 
by the increasing genomic information. New technologies such as automated protein 
expression and puriﬁcation systems, used for the generation of capture molecules and the 
need for analysis of whole ‘proteomes’ will be a driving force for fast developments within 
the ﬁeld of protein microarray technology.
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1.5 Protein Microarrays in vaccine development against GAS
A systematic characterization of the composition and structure of the bacterial cell-
surface proteome and its complexes can provide an invaluable tool for its comprehensive 
understanding. 
The knowledge of protein complexes composition and structure could oﬀer new, more 
eﬀective targets for a more speciﬁc and consequently eﬀective immune response against a 
complex instead of a single protein.
Large-scale protein-protein interaction screens are the ﬁrst step towards the identiﬁcation 
of complexes and their attribution to speciﬁc pathways. Currently, several methods exist 
for identifying protein interactions and protein microarrays provide the most appealing 
alternative to existing techniques for a high throughput screening of protein-protein 
interactions in vitro under reasonably straightforward conditions. 
In this study approximately 100 proteins of Group A Streptococcus predicted to be 
secreted or surface exposed by genomic and proteomic approaches were puriﬁed in a His-
tagged form and used to generate protein microarrays on nitrocellulose-coated slides. 
Spotted GAS proteins have been selected on the basis of the bioinformatic and proteomic 
analysis (Rodriguez-Ortega, Norais et al. 2006) that integrated the reverse vaccinology 
approach (Figure 1.11) and included mostly protein from M1 SF370 strain lipoproteins 
known to be surface exposed some of which containing the LPXTG anchor domain or 
know virulence factors.
To identify protein-protein interactions each puriﬁed protein was then labeled with 
biotin, hybridized to the microarray and interactions were detected with Cy3-labelled 
streptavidin. Only reciprocal interactions, i. e. binding of the same two interactors 
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irrespective of which of the two partners is in solid-phase or in solution, were taken as 
bona ﬁde protein-protein interactions. Using this approach, we have identiﬁed 20 
interactors of one of the potent toxins secreted by GAS and known as superantigens. 
Several of these interactors belong to the molecular chaperone or protein folding catalyst 
families and presumably are involved in the secretion and folding of the superantigen. In 
addition, a very interesting interaction was found between the superantigen and the 
substrate binding subunit of a well characterized ABC transporter. This ﬁnding opens a 
new perspective on the current understanding of how superantigens are modiﬁed by the 
bacterial cell in order to become major players in causing disease. 
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Figure 1.11 Screening for potential vaccine candidates:protein 
microarray results are combined with candidates obtained 
through genomics and proteomics approach.
2. Materials and Methods
2.1 Bacterial growth medium
- LB (Luria Bertani)
Composition:
Trypton (10g/L), Yeast extract (5g/L), NaCl (10g/L) pH 7.6; ampicillin (100μg/ml)
- HTCM (High Throughput Complex Medium)
Composition: 
Glycerol: 15 g/L (or Glucose); MgSO4: 0,5 g/L (2mM); YE(difco): 30 g/L; K2HPO4: 
16 g/L; KH2PO4: 6 g/L; Ampicillin: 200 mg/L; pH: 7.35
2.2 Cloning of GAS proteins
GAS genes encoding for selected protein were cloned into vectors suitable for expression 
in E. coli.
The vector used were pET21b(+) (plasmid for expression by T7 RNA polymerase, 
Novagen, Figure 2.1), which allows the expression of recombinant proteins with a 6 
histidine residues tag and pGEXNNH (Amersham Bioscience, Figure 2.2) that delivers 
the protein fused also with Glutathione-S.transferase (GST). 
The pET-21b(+) vector carry an N-terminal T7 Tag®sequence plus an optional C-
terminal His Tag® sequence and carry an ampicillin selectable marker. 
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Unique sites are shown on the circle map. Note that the sequence is numbered by the 
pBR322 convention, so the T7 expression region is reversed on the circular map. The 
cloning and expression region of the coding strand transcribed by T7 RNA polymerase is 
shown below in Figure 2.1. The f1 origin is oriented so that infection with helper phage 
will produce virions containing single-stranded DNA that corresponds to the coding 
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pET-21b(+) sequence landmarks
——————————————
T7 promoter   311-327 
T7 transcription start  310 
T7 Tag coding sequence  207-239 
Multiple cloning sites 
(BamH I - XhoI)   158-203 
His Tag coding sequence  140-157 
T7 terminator   26-72 
lacI coding sequence  714-1793 
pBR322 origin   3227 
bla coding sequence  3988-4845 
f1 origin    4977-5432 
Figure 2.1. Map of pET-21b(+) expression vector and detail of the T7 cloning expression region
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strand. Therefore, single-stranded sequencing should be performed using the T7 
terminator primer.
Restriction sites (usually NdeI and XhoI) are determined among the ones available in the 
vector polylinker depending on the speciﬁc sequence of interest and primers are designed 
consequently, usually 20 to 30 bp long with a Melting Temperature ranging from 52 to 
54° C. 
The insert sequence is ampliﬁed by PCR using Pfu Ultra (Stratagene) as follows:
PCR mix composition: 100 ng GAS genomic DNA; 10 μl buﬀer 10x; 2 μl dNTPs 10 
mM each; 2 μl taq; 20 pmol primerF (Forward); 20 pmol primerR (Reverse); H2O to 
reach 100 μl ﬁnal volume.
PCR cycle steps: 2 minutes at 98°C; 30 seconds at 98°C, 30 cycles; 50 seconds at 50°C; 
X minutes (1 minute every 1000 bp of the amplifying sequence) at 72°C and 7 minutes 
at 72°C. PCR products are the controlled on agarose gel and puriﬁed with QIAGEN 
PCR puriﬁcation kit or by gel extraction (QIAGEN gel extraction kit).
Puriﬁed PCR product and vector are digested with the selected restriction enzymes (New 
England BioLabs) in ~60 U of each enzyme in 100 μl ﬁnal volume for 3 hours or over 
night. Digested PCR product is puriﬁed (QIAGEN PCR puriﬁcation kit) and the 
pET21b(+) vector is digested over night at 37°C with the same restriction enzymes (4 μg 
of plasmid DNA and 40 U of each enzyme in 100 μl ﬁnal volume). The vector is then 
dephosphorylated for 1 hour at 37°C adding 2 μl (20 Units) of alkaline phosphatase (calf 
intestinal, CIP, New England BioLabs) in the same digestion buﬀer and puriﬁed by gel 
extraction (QIAGEN gel extraction kit).
Ligation reaction between the plasmid and the vector is performed (100 ng total between 
plasmid DNA and digested PCR in 10 μl ﬁnal volume) for 3 hours at room temperature. 
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Electrocompetent E. coli BL21(DE3) for pET or BL21 for pGEX are transformed with 1 
μl of ligation reaction. One milliliter of LB (or SOC) is added and bacteria are grown at 
37°C for 45 minutes and plated on LB with 100 μg/ml ampicillin plates. Single 
ampicillin resistant colonies were selected and checked for the presence of recombinant 
plasmid by colony PCR. E.coli BL21(DE3) clones containing the recombinant plasmid 
are ﬁnally checked for the expression of the recombinant protein. The pGEX vector used 
has been engineered in-house by introducing a portion of the polylinker present in the 
pET vector to use the same restriction enzymes used during cloning. 
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Figure 2.2. The pGEX expression vector and the in-house engineered polylinker.
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2.3 Protein expression
Expression of His-tagged proteins
Selected clone is ﬁrst grown in a 25 ml LB with 0.1 μg/ml ampicillin starter colture over 
night at 37°C in agitation at 180 rpm. 
The starter colture is then diluted in 500 ml of the above growth medium in a 2 liter ﬂask 
and grown at 30°C in agitation at 180 rpm. The colture O.D.600 is periodically measured.
When colture O.D.600 reaches a value between 0.4 and 0.7, IPTG 0.5M (1mM ﬁnal 
concentration) is added for induction.
The colture is grown for 3.5 hours at 25°C in agitation 180 rpm.
Expression of Gst-Tagged proteins
Selected clone is ﬁrst grown in a 25 ml LB with 0.1 μg/ml ampicillin starter colture over 
night at 37°C in agitation at 180 rpm. 
The starter colture is then diluted in 500 ml of the above growth medium in a 2 liter ﬂask 
and grown at 25°C in agitation at 180 rpm. The colture O.D.600 is periodically measured.
When colture O.D.600 reaches a value between 0.7 and 0.8, IPTG 0.5M (1mM ﬁnal 
concentration) is added for induction.
The colture is grown for 3.5 hours at 25°C in agitation 180 rpm.
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Protein expression using HTFS (High Throughput Fermentation System)
This system is based on in-house adapted 50 ml Falcon vials, prepared by boring three 
round holes in the cap: one in the center for air intake and two lateral for air out. The air 
intake will host a 2 ml Falcon pipette connected to a ﬂuximeter and the air outtake will 
be ﬁltered by two shortened ART1000 ﬁltered tips (Figure 2.3).
Selected clone is then grown in 4 ml Glucose-HTCM at 37°C in agitation until bacteria 
reach exponential phase. Thirty ﬁve microliters of this colture are inoculated into a 
prepared Falcon vial containing 35 ml of Glycerol-HTCM and 50 μl PPC (poly 
propylene carbonate anti-foam solution, 1/10 diluted).
Falcon vials are placed on a heater set to 26.1°C (to keep the temperature from dropping 
under 26°C) and air ﬂux (which also provides agitation) is set to 3 VVM (volume gas / 
[volume liquid / minute]).
The bacteria are grown for 36 hours, then the falcon vial caps are replaced with new ones 
and vials are centrifuged at 4000 xg at 4°C for 40 minutes. Supernatant is discarded and 
pellets are stored at -20°C.
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Figure 2.3. HTFS machinery has 
been developed in house in the 
Novartis Vaccines Fermentation 
Lab, by Erwin Swennen and 
colleagues. The system is composed 
by 2 block heaters holding a 
maximum number of 24 standard 
50 ml Falcon vials with 3 holes 
manually drilled in the cap. Filtered 
ART1000 tips are used as air-out 
and the central hole is attached to a 
ﬂuximeter set to 3 VVM.
2.4 Protein puriﬁcation
Poly-Prep Column His-Tagged protein puriﬁcation
Pellets are thaw at room temperature and resuspended in 10 ml B-PER? (Bacterial-
Protein Extraction Reagent, Pierce); 20 μl MgCl2 50 mM (0.1mM); 100μl DNAse I 
(100 Kunits Sigma D-4263) in PBS; 100 μl lysozyme (Sigma L-7651) 100 mg/ml in PBS 
(1 mg/ml ﬁnal concentration).
Lysis solution is transferred in 50 ml centrifuge vials and is kept at room temperature fore 
40 minutes and vortexed a few times and then spun at 40000 g for 25 minutes. 
Poly-Prep column are prepared and equilibrated with 1 ml Ni-Activated Chelating 
Sepharose Fast Flow in 50mM phosphate buﬀer and 300mM NaCl at pH 8 and 
supernatant is loaded. Column ﬂow through is discarded. 
Ten milliliters of 20 mM imidazole, 50 mM phosphate, 300 mM NaCl buﬀer at pH 8 is 
added to discard impurities.
Proteins bound to the column are eluted with 4.5 ml of 250 mM imidazole, 50mM 
phosphate, 300 mM NaCl buﬀer at pH 8 and collected in three 1.5 ml fractions. 15μl 
DTT (Dithiothreitol) 200 mM (2mM ﬁnal concentration) is added to each fraction.
Protein concentration of each fraction is estimated by Bradford assay and 10 μg of 
protein are loaded on SDS-PAGE gel.
Proteins are then stored at 4°C
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Poly-Prep Column GST-Tagged protein puriﬁcation
Pellets are thaw at room temperature and resuspended in 10 ml B-PER? (Bacterial-
Protein Extraction Reagent, Pierce); 20μl MgCl2 50 mM (0.1mM); 100μl DNAse I (100 
Kunits Sigma D-4263) in PBS; 100μl lysozyme (Sigma L-7651) 100 mg/ml in PBS (1 
mg/ml ﬁnal concentration).
Lysis solution is transferred in 50 ml centrifuge vials and is kept at room temperature for 
40 minutes and vortexed a few times and then spun at 40000 xg for 25 minutes. 
Poly-Prep column are prepared and equilibrated with 0,5 ml Glutathione-Sepharose 4B, 
washed with 2 ml H2O and 10 ml PBS, pH 7.4 and supernatant is loaded. Column ﬂow 
through is discarded. 10 ml of PBS, pH 7.4 is added to discard impurities. Proteins 
bound to the column are eluted with 50 mM TRIS and 10mM reduced glutathione at 
pH 8 and collected in three 1.5 ml fractions. 15μl DTT 200 mM (2mM ﬁnal 
concentration) is added to each fraction. Protein concentration of each fraction is 
estimated by Bradford assay and 10μg of protein are loaded on SDS-PAGE gel. Proteins 
are then stored at 4°C
AKTA System
Every “System” module can perform three puriﬁcations. The biomass  is resuspended in 
10 ml B-PER? (Bacterial-Protein Extraction Reagent, Pierce cat. 78266); 10 μl of 100 
mM MgCl2 solution (0,1 mM ﬁnal concentration); 50 μl DNAse I equivalent to 100 K-
Units (Sigma D-4263) in PBS and 100 μl of 100 mg/ml lysozyme solution (Sigma 
L-7651) in PBS equivalent to 10 mg (1 mg/ml ﬁnal concentration).
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Resuspended bacteria are transferred in 50 ml Falcon tubes, kept there for 30 to 40 
minutes and vortexed a few times in order for the lysis reagents to act and then 
centrifuged at 35000 xg.  The pellet is discarded and the clear supernatant is collected for 
chromatographical analysis with AKTAxpress. The absorbance at 280 nm is constantly 
read by the system to monitor the following puriﬁcation.
1°) AFFINITY CHROMATOGRAPHY: the sample is loaded on a HisTrap FF column 
(Nickel activated) conditioned in 300 mM NaCl, 50 mM Na-Phosphate pH 8.00. The 
column is then washed in 20 mM Imidazole in equilibrium buﬀer and the protein is 
eluted with 500 mM Imidazole (in the same buﬀer). All ﬂux rates are set to 1 ml/minute.
 
2°) DESALTING: the goal of this step is to prepare the sample for the ion exchange 
column. The HisTrap FF column eluate is loaded on the 5 ml Hi-Trap Desalting, serially 
attached, conditioned in 50 mM Tris-Cl pH 8.00 and the sample is eluted with 
equilibrium buﬀer with a 5 ml/minute ﬂux rate.
 
3°) ION EXCHANGE: the sample eluted from desalting is loaded at 1 ml/minute ﬂux 
rate on a 1 ml Hi-Trap Q HP column conditioned in 50 mM Tris-Cl pH 8.00, 
previously washed with the same buﬀer. The ﬂow through is automatically collected by 
default (2 ml for each fraction). Proteins bound to the column are eluted with a NaCl 
gradient from 0 to 500mM in ten column volumes (CV), collecting 1 ml fractions 
followed by a 10CV step in 1.0 M NaCl in equilibrium buﬀer.
Every step is performed automatically by AKTAxpress.
 COLUMN POSITION
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POSITION N° COLUMN  Column Volume
1  HisTrap FF   1 ml
2  HisTrap FF   1 ml
3  HisTrap FF   1 ml
4  HiTrap Q HP  1 ml
5  HiTrap Desalting  3 x 5 ml
INLET  BUFFER:
INLET BUFFER
A1  300 mM NaCl, 50 mM Na-phosphate pH 8.00.
B1  500 mM Imidazole, 300 mM NaCl, 50 mM Na-Phosphate pH 8.00.
A2  50 mM Tris-Cl pH 8.00.
B2  1 M NaCl 50 mM Tris-Cl pH 8.00.
A3  20 mM Imidazole, 300 mM NaCl, 50 mM Na- Phosphate pH 8.00.
A5  H2O.
A6  0,5 M NaOH.
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2.5 Tagless Proteins
To obtain puriﬁed proteins without a Histidine tag, a TEV (Tobacco Etch Virus) cleavage 
site was inserted at the N-terminal of the protein before the 6 Histidines.
The “PIPE” method (Polymerase Incomplete Primer Extension) was used for cloning 
these speciﬁc proteins (Klock, Koesema et al. 2008; Klock and Lesley 2009). The vector 
pSpeedET (Figure 2.5) was used that provided the cells with kanamycin resistance and 
therefore expression protocol was adapted to use kanamycin (30 μg/ml) instead of 
ampicillin (Figure 2.4).
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Figure 2.4. Schematics of proposed PIPE mechanism and methods. The light gray lines represent 
template DNA. The black lines with dashed or dotted ends represent the primers with 50 
complementary extensions. The black square dashes represent sequences complementary to each other as 
do the black circles. The straight dark gray lines represent complete strand synthesis. The dashed dark 
gray lines represent heterogeneous primer extension resulting from PIPE. (a) Progression of PIPE during 
normal PCR ampliﬁcation. (b) The PIPE Entry Cloning method. (c) Primer design guidelines and 
method for PIPE Mutagenic Cloning for creating insertion, substitution and deletion mutants (Klock, 
Koesema et al. 2008). 
Normal PCR reactions generate mixtures of incomplete extension products. Using 
classical primer design rules and PCR, short, overlapping sequences are introduced at the 
ends of these incomplete extension mixtures which allow complementary strands to 
anneal and produce hybrid vector/insert combinations.  These hybrids are directly 
transformed into recipient cells without any post-PCR enzymatic manipulations.
Figure 2.5. Detail of the vector used for obtaining tagless proteins exploiting the TEV cleavage site 
cloned between the protein and the Histidine tag. 
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2.6 Other Protein assays
Bradford Assay
The Bradford assay is the commonly used technique to determine concentrations of 
puriﬁed proteins in solution. The method of Bradford is the basis of the Bio-Rad Protein 
Assay and it involves the addition of an acidic dye to protein solution, and subsequent 
measurement at 595 nm with a spectrophotometer (an ULTROSPEC® 3000 Pharmacia 
Biotech was used). A diﬀerential color change of a dye occurs in response to various 
concentrations of the protein (Bradford 1976). The absorbance maximum for an acidic 
solution of Coomassie®Brilliant Blue G-250 dye shifts from 465 nm to 595 nm when 
binding to protein occurs (Reisner, Nemes et al. 1975; Sedmak and Grossberg 1977). The 
Coomassie blue dye binds to primarily basic and aromatic amino acid residues, especially 
arginine (Compton and Jones 1985). Spector and colleagues (Spector 1978) found that 
the extinction coeﬃcient of a dye-albumin complex solution was constant over a 10-fold 
concentration range. Thus, Beer’s law may be applied for accurate quantiﬁcation of a 
protein by selecting an appropriate ratio of dye volume to sample concentration.
Samples were prepared using 1 part Dye Reagent Concentrate with 4 parts PBS and at 
least two diﬀerent dilutions of the protein so that both absorbance values (A595) are 
within the optimal reading range of the instrument (A595 between 0.2 and 0.8).
The determined protein concentration is: 
[(A595 Sample) - (A595 Reference Sample)] * dilution factor
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Considering the obtained protein concentration 5 to 10 μg are loaded on gel to verify the 
result of the Bradford assay.
A280 reading to determine protein concentration
When the Bradford assay failed to provide accurate results or when it was not 
recommended to use any protein amount in concentration determination assays the A280 
reading provided an appealing alternative approach for protein concentration 
determination without wasting the protein.
To use this method the protein sequence must be known and provided to computer 
software (such as VectorNTI or free online tools at ExPASy Proteomics Server) that 
returns the protein concentration at which A280 is 1. This concentration value is used to 
determine the concentration of the sample based on its A280 reading.
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2.7 Protein chip
Design
A pool of 93 proteins has been selected among those predicted and found to be on the 
Group A Streptococcus cell surface or secreted. Designing the chip layout is a key step in 
microarray based research to overcome some of the technique limitations. For this 
particular experiment, because of the number of samples and controls we chose a 12-pin 
array setup with 384 wells plates. The pins were arranged in two rows of six and each one 
printing a grid.
Due to the morphology of the BioRad ChipWriterTM Pro used to print the microarray 
and capable also of printing nucleic acids, the carry-over of protein from one spot to the 
next one is the major limitation. Therefore half of the spots in the microarray layout are 
considered empty, ﬁlled with only the H2O spotted, to control and avoid carry-over. 
These spots will be analyzed after every experiment looking for ﬂuorescence signals that 
will determine the background value.
The design also included various types of controls, mostly serial dilutions of proteins or 
antibodies and they have all been arranged to be spotted at the side of the grid for the 
most user friendly analysis possible that ﬁtted the sample number and the 12 pin array. 
Double water spots were included after the ﬁrst four spots of the controls serial dilutions 
to avoid carry over of certain types of controls (e.g. antibodies) and for additional 
background control (Figure 2.6).
This particular design is able to ﬁt protein-protein interaction experiments using various 
detection techniques: biotinylated protein and ﬂuorophore conjugated streptavidin as 
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well as mouse or rabbit protein speciﬁc antibody and conjugated secondary antibody. 
Both Cy3 and Cy5 ﬂuorophores can be used.
42
277His 294His 384His 509His BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 529His 4141His 
M12
80His 
M77
SpeA His
Mo-IgG  
0.008
Mo-IgG  
0.016
Mo-IgG 
0.031
Mo-IgG 
0.063
Mo-IgG  
0.125
Mo-IgG  
0.25
Mo-IgG  
0.5
Mo-IgG   
1
157His 160HisM6 166GN 190His 107HisM28 103GN 101GN 99His 195His 208GN 219His 249His 95His 89His 85His 81His
GSTNN NNHis Raf GBS 665 Actin 
0.063
Actin 
0.125
Actin 
0.25
Actin 0.5
84His 88His 92His 97His 220His 217GN 205His 191His 100HisM
3
102HisM
3
105GN
109His 
M28
179His 165nat 158His 110His
15His 23His 30GN 45GN Gst90 m1His 4134His M12 511His 76GN 67GN 60His 49His 57nat 65His 75His 77GN 477His 327His 282His 251His 36His 25His
16p2 
His
5His
277His 294His 384His 509His BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 529His
4141His 
M12
80His 
M77
SpeA His
Mo-IgG  
0.008
Mo-IgG  
0.016
Mo-IgG 
0.031
Mo-IgG 
0.063
Mo-IgG  
0.125
Mo-IgG  
0.25
Mo-IgG  
0.5
Mo-IgG   
1
157His
160His 
M6
166GN 190His
107His 
M28
103GN 101GN 99His 195His 208GN 219His 249His 95His 89His 85His 81His
GSTNN NNHis Raf GBS 665
Actin 
0.063
Actin 
0.125
Actin 
0.25
Actin 0.5
84His 88His 92His 97His 220His 217GN 205His 191His
100HisM
3
102HisM
3
105GN
109His 
M28
179His 165nat 158His 110His
15His 23His 30GN 45GN Gst90 m1His
4134His 
M12
511His 76GN 67GN 60His 49His 57nat 65His 75His 77GN 477His 327His 282His 251His 36His 25His
16p2 
His
5His
264His 290His 380His 504His BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 BSA Cy3 527His
4137GN 
M12
m1His
Gst98 
M3
Mo-IgG  
0.008
Mo-IgG  
0.016
Mo-IgG 
0.031
Mo-IgG 
0.063
Mo-IgG  
0.125
Mo-IgG  
0.25
Mo-IgG  
0.5
Mo-IgG   
1
137His
159a 
HisM6
165His 187His 108GN
104His 
M3
102His 100GN 193His 206His 219GN 242His 96His 91His 86His 82His
101GN 
0.48
101GN 
0.95
101GN  
1.9
101GN 3.8
Actin 
0.063
Actin 
0.125
Actin 
0.25
Actin 0.5
82His 86His 91His 96His 242His 219GN 206His 193His 100GN 102His
104HisM
3
108GN 187His 165His
159a 
HisM6
137His
5FHis 18His 29His 40nat Gst98M3 m3HisM3
4137GN 
M12
527His 76His 67His 63His 56His 56His 63His 67His 76His 504His 380His 290His 264His 40nat 29His 18His 5F His
264His 290His 380His 504His
BSABio 
0.004
BSABio 
0.008
BSABio 
0.016
BSABio 
0.031
BSABio 
0.063
BSABio 
0.125
BSABio 
0.25
BSABio 
0.5
527His
4137GN 
M12
m1His
Gst98 
M3
RaIgG 
0.008
RaIgG 
0.016
RaIgG 
0.031
RaIgG 
0.063
RaIgG 
0.125
RaIgG 
0.25
RaIgG 0.5 RaIgG 1
137His
159a 
HisM6
165His 187His 108GN
104HisM
3
102His 100GN 193His 206His 219GN 242His 96His 91His 86His 82His
SpeA 0.5 SpeA 1.0 SpeA 2.0 SpeA 4.0
Fibronec 
0.063
Fibronec 
0.125
Fibronec 
0.25
Fibronec 
0.5
82His 86His 91His 96His 242His 219GN 206His 193His 100GN 102His
104His 
M3
108GN 187His 165His
159a 
HisM6
137His
5FHis 18His 29His 40nat Gst98M3
m3His 
M3
4137GN 
M12
527His 76His 67His 63His 56His 56His 63His 67His 76His 504His 380His 290His 264His 40nat 29His 18His 5F His
251His 282His 327His 477His
BSABio 
0.004
BSABio 
0.008
BSABio 
0.016
BSABio 
0.031
BSABio 
0.063
BSABio 
0.125
BSABio 
0.25
BSABio 
0.5
511His
4134His 
M12
m3His 
M3
Gst90
RaIgG 
0.008
RaIgG 
0.016
RaIgG 
0.031
RaIgG 
0.063
RaIgG 
0.125
RaIgG 
0.25
RaIgG 0.5 RaIgG 1
110His 158His 165nat 179His
109His 
M28
105GN
102His 
M3
100His 
M3
191His 205His 217GN 220His 97His 92His 88His 84His
76GN  
0.12
76GN 
0.24
76GN 
0.48
76GN 
0.97
Fibronec 
0.063
Fibronec 
0.125
Fibronec 
0.25
Fibronec 
0.5
81His 85His 89His 95His 249His 219His 208GN 195His 99His 101GN 103GN
107His 
M28
190His 166GN
160HisM
6
157His
5His 16p2 His 25His 36His
SpeA 
HisM3
80His 
M77
4141His 
M12
529His 77GN 75His 65His 57nat 49His 60His 67GN 76GN 509His 384His 294His 277His 45GN 30GN 23His 15His
251His 282His 327His 477His
BSABio 
0.004
BSABio 
0.008
BSABio 
0.016
BSABio 
0.031
BSABio 
0.063
BSABio 
0.125
BSABio 
0.25
BSABio 
0.5
511His
4134His 
M12
m3His 
M3
Gst90
RaIgG 
0.008
RaIgG 
0.016
RaIgG 
0.031
RaIgG 
0.063
RaIgG 
0.125
RaIgG 
0.25
RaIgG 0.5 RaIgG 1
110His 158His 165nat 179His
109His 
M28
105GN
102His 
M3
100His 
M3
191His 205His 217GN 220His 97His 92His 88His 84His
219GN 
0.39
219GN 
0.78
219GN 
1.55
219GN  
3.1
Fibronec 
0.063
Fibronec 
0.125
Fibronec 
0.25
Fibronec 
0.5
81His 85His 89His 95His 249His 219His 208GN 195His 99His 101GN 103GN
107His 
M28
190His 166GN
160His 
M6
157His
5His 16p2 His 25His 36His
SpeA 
HisM3
80His 
M77
4141His 
M12
529His 77GN 75His 65His 57nat 49His 60His 67GN 76GN 509His 384His 294His 277His 45GN 30GN 23His 15His
Figure 2.6. Microarray layout. Surface GAS proteins are represented by orange boxes. H20 spotter between proteins to avoid 
carry over is highlighter in blue. Experimental and spotting controls in other colors.
Preparation
Puriﬁed GAS proteins are dialyzed in PBS and eventually concentrated to obtain a 
concentration of 0.5 mg/ml or higher. Each protein is then loaded in four wells (6 μl per 
well) of a 384 well polypropylene micro plate. 
Each plate contains three standard curves: Mouse IgG, Cy3 and Cy5-labelled BSA 
(Amersham Biosciences) and biotin-labeled BSA. All samples are spotted on 
nitrocellulose slides by using the VersArray ChipWriterTM Pro System (BIO-RAD) 
equipped with TeleChem quill pins (TeleChem International Sunnyvale, CA, USA). The 
pins are previously controlled with optical microscope to check for dirt or damaged 
heads.
Spotting
Following the ﬁrst printing of each sample, the pins are washed 7 times (6 seconds each), 
subjected to sonication (1 second) and dried under vacuum (2 seconds). After each 
printing process, each slide is scanned to check the signals of the Cy3 and Cy5-labeled 
BSA curves.
Hybridization
Slides are washed with PBS at 20°C for 5 minutes and then with TPBS (0.05% Tween 20 
in PBS) at 20°C for 1 minute followed by 1 hour incubation in the dark for blocking 
with shaking in 5% Top Block (Fluka-BioChemiKa, Cat. n° 37766) in TPBS. Slides are 
incubated with protein probe (in 3% Top Block in PBS) for 1 h at 20°C in the dark and 
then washed 3 times (3 minutes each time) in TPBS.
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Staining 
Biotinylated protein/streptavidin:
Streptavidin-Cy3 (1:100 dilution in 3% Top Block in PBS) is added and incubation is 
prolonged for 1 hour at 20°C in the dark. Slides are then washed twice with TPBS (1 
minute each time), twice with PBS (1 minute) and once with sterile milliQ H2O (30 
seconds). 
Protein/speciﬁc antibody:
Slides are incubated with probe-speciﬁc primary antibody (1:20000 ﬁnal dilution in 3% 
Top Block in PBS) for 1 hour at 20°C in the dark and then washed 3 times (1 minute 
each time) in TPBS then Alexa 546 anti-Rabbit IgGs (1:1000 dilution in 3% Top Block 
in PBS) are added and incubation is prolonged for 1 hour at 20°C in the dark. 
Slides are then removed from the incubation chamber, washed once with sterile milliQ 
H2O and air-dried.
Scan of hybridized slides
The ﬂuorescence signal was detected using a high resolution (10 mpixel size) scanner 
ScanArray 5000 Unit (Packard, Billerica, MA, USA) and using lasers to detect the 
speciﬁc ﬂuorophore used. The signal was then quantiﬁed with the program Imagene 7.5 
(Biodiscovery Inc, CA, USA). The data collected were analyzed using the in-house 
developed program "Protein Chip". 
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The ﬂuorescence signal of each protein was calculated as an average intensity of 
ﬂuorescence of the four replicates minus the background ﬂuorescence intensity. 
To determine binding on a protein-probe to another protein cutoﬀ ﬂuorescence intensity 
value of 5000 was established as equal to the average values of intensity of the negative 
controls (protein contamination of E. coli) plus three times the value of standard 
deviation. Average intensities of ﬂuorescence below this value were discarded.
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2.8 Surface plasmon resonance analysis
Proteins immobilization
Experiments were performed at 25°C with a BIACORE T100 instrument (Biacore AB, 
Uppsala, Sweden). All the reagents were purchased from GE Healthcare, whereas not 
speciﬁed. Proteins SpeI, AdcA and Lmb were immobilized on a carboxymethilated 
dextran coated (CM5) sensor chip by amine coupling. 
Brieﬂy, a mixture of 0.2 M 1-ethyl-3-diaminopropyl-carbodiimide (EDC) and 0.05 M 
N-hydroxysuccinimide (NHS) was used for sensor chip surface activation. Proteins pre-
concentrated in 0.01M sodium acetate pH 4.5 were injected at 50μg/ml for 7 minutes 
and eventually 1M Ethanolamine pH 8.5 was used to block remaining activated groups. 
Approximately 2000 Rus of immobilized material were achieved for the three proteins.
As for monomeric biotinylated SpeI, immobilization on a streptavidin coated (SA) sensor 
chip was obtained by 5 minutes injection of 50 μg/ml of the above mentioned protein in 
HBS-EP+ buﬀer (10 mM Hepes, NaCl 150 mM, EDTA 3.4 mM, p20 0.05%, pH 7.4) 
at a ﬂow rate of 5 μl/min.
In all the following described experiments an empty ﬂow cell was used as blank reference 
and subtracted sensorgrams were used for evaluation.
Zn++ inﬂuence on binding
Binding on immobilized proteins was investigated either in the absence or in the presence 
of zinc ions. A solution containing 10 mM HEPES, 150 mM NaCl, 0.05% p20, pH 7.4 
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(HBS-N) with increasing ZnCl2 (Sigma-Aldrich) concentrations ranging from 100 nM 
to 50 μM was used as running buﬀer. Proteins diluted in the same buﬀer at 50 and 25 
μg/ml were injected for 3 minutes at a ﬂow rate of 20 μl/ml and regeneration of sensor 
chip surface was achieved with a 30 seconds pulse of 500 nM NaCl and 10 mM EDTA. 
HBS-EP+ was used as running and dilution buﬀer for the same experiments without 
Zn2+.
koﬀ ranking
Selected proteins were diluted at 25μg/ml in HBS-N/5μM Zn++ and eventually injected 
over the three proteins simultaneously for 3 minutes at a ﬂow rate of 20 μl/min. 
Dissociation was followed for 400 seconds and regeneration was performed as already 
described. Whenever possible dissociation rate constants were calculated with 
“BiaEvaluation 4.1 software”.
Kinetics characterization
Proteins SpeI and AdcA were further characterized for their association rate and aﬃnity 
constants at equilibrium versus immobilized proteins.
Kinetics experiments were performed by injecting increasing concentration of the 
proteins in HBS-N/5 μM Zn2+ over the sensor chip surface for 3 minutes at a ﬂow rate of 
20 μl/minute. Complexes were left to dissociate for 500 seconds and regeneration was 
obtained with a 30 seconds pulse of 500 nM NaCl and 10 mM EDTA.
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Dilutions of each protein were prepared shortly before injection in order to minimize 
potential aggregation. kon, koﬀ and KD were calculated with 1:1 Langmuir model with 
“BiaEvaluation 4.1”.
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3. Results
3.1 Obtaining the proteins for protein-protein interactions
For Microarray analysis of S. pyogenes protein-protein interactions a high-throughput 
system for expression and puriﬁcation was implemented involving a High Throughput 
Fermentation System (HTFS) for protein expression and AKTAxpress chromatography 
system to obtain a highly puriﬁed proteins in high-throughput manner (Figure 3.1).
From a collection of 93 selected proteins (Table 3.1), carrying a 6-Histidine tag at the 
carboxyl terminus, 82 were successfully expressed in E. Coli using HTFS with only 35 ml 
of HTCM growth medium and auto-induction, reaching a ﬁnal OD590 value between 7 
and 10, corresponding to 0.5 to 0.75 grams of total biomass and 1 to 20 mg of total 
recombinant protein. The system can deliver 48 cultures in 2 days and a total of 192 
proteins per month per technician.
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Figure 3.1. Puriﬁed SpeI on AKTAxpress before (A) and after (B) the cleavage of the His-tag by TEV 
protease. 
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Table 3.1. Annotation and predicted localization of proteins used for microarrays.
Protein predicted 
localization N° Annotation (SF370 NCBI) Locus
Energy metabolism lmb; mtsA; tlpA; SPy0163; SPy1228 
Lipoprotein 23
Transport and binding 
proteins
fhuD; oppA; pstS; SPy0317; SPy1274; 
SPy1795
 
Cell envelope dppA; SPy0604; SPy1290
Unknown function
inlA; malX; prsA; SPy0210; SPy0252; 
SPy0457; SPy0778; SPy1294; SPy1390
Amino acid biosynthesis cysM
Cell envelope
isp; prtS; SPy0793; SPy0843; SPy1326; 
M6_Spy0160
Cell wall/membrane 
biogenesis SpyM3_0104
Cellular processes hlyA1; emm3; M6_Spy0159
Central intermediary 
metabolism glmS; SPy0380
Energy metabolism guaA; pulA 
Membrane 45
Fatty acid and phospholipid 
metabolism accA
Protein fate scpA
Transport and binding 
proteins
SPy2009; SPy2033; M6_Spy0157; 
MGAS2096_Spy0110; MGAS2096_Spy0115; 
MGAS2096_Spy0119
Unknown function
cbp; cpa; emm1; fabK; ftsZ; grab; mf; pepQ; 
prgA; SPy0128; SPy0130; SPy0838; 
SPy0872; SPy1054; SPy1686; SPy1874; 
SPy1939; M5005_Spy0107; SpyM3_0100; 
SpyM3_0102; M28_Spy0109; SpyM50106 
Cell envelope isp2; mur1.2
Cellular processes hylA; ska; speC; speG; speI; speJ
Outside 20
Central intermediary 
metabolism SPy1718
Unknown function
adcA; mf3; sic; slo; SPy0019; SPy0925; 
SPy1037; SPy1491; SPy1733; SPy1813; 
SPy2066
Cytoplasm 2
Cell envelope fbp
Energy metabolism eno
Unknown 3 gid; SPy0652; SPy1959
The remaining 11 proteins are characterized by low expression levels and required a 
greater culture volume and IPTG for induction of expression.
Particularly when studying protein-protein interactions it is very important to work with 
proteins as pure as possible and obtained in a high throughput manner.  The AKTAxpress 
3-step puriﬁcation system is a good compromise between quality and time. The system 
delivers up to 48 His-tagged proteins per month per technician with purity levels of 75% 
to 90%. All proteins used in this study were puriﬁed using AKTAxpress and because of 
its versatility it could be used for both His- and GST-tagged proteins.
3.2 Biotinylation of GAS proteins
Even though the microarray design allows detection of binding between the protein 
probe and the array by using probe-speciﬁc mouse or rabbit sera, the detection of 
interactions in our experimental approach was obtained using biotinylated protein probes 
and Cy3-labelled streptavidin, since this is the most commonly used approach in 
microarray publications in the literature.
Each puriﬁed GAS protein from the 93 selected proteins was biotinylated using an 
amine-reactive biotinylation reagent. This reagent is able to attach a biotin molecule to 
the amine groups of all the exposed lysine residues by using a biotin-protein molar ratio 
of 20:1. To avoid biotinylation of all lysines, should a lysine be part of an active binding 
site, the molar ratio has been lowered to 3:1.  Ten of the biotinylated proteins were 
analyzed by mass spectrometry and their biotinylated lysines were mapped.
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A representative example of such an analysis is given in Fig. 3.1, which shows that in our 
experimental conditions Spy1007 (SpeI), that contains 21 lysine residues in its sequence, 
was biotinylated only at one, two or three lysine residues per protein molecule and biotin 
was linked only to Lys102 and/or Lys209 and/or Lys227. Analogous results were 
obtained for the other proteins analyzed by mass spectrometry. In all cases, between one 
and three lysine residues were biotinylated and the modiﬁcation was observed to occur at 
a restricted number of sites. 
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MSSVGVINLR NLYSTYDPTE VKGKINEGPP FSGSLFYKNI PYGNSSIELK
VELNSVEKAN FFSGKRVDIF TLEYSPPCNS NIKKNSYGGI TLSDGNRIDK
KNIPVNIFID GVQQKYSYTD ISTGSTDKKE VTIQELDVKS RYYLQKHFNI
YGFGDVKDFG RSSRFQSGFE EGNIIFHLNS GERISYNLFD TGHGDRESML
KKYSDNKTAY SDQLHIDIYL VKFNKLEHHH HHH
Figure 3.2. Mass spectrometry analysis of SpeI biotinylation. Three forms of the biotinylated protein plus the 
non biotinylated form are present in the solution (A). After tryptic digestion only three lysins appear to have 
acquired a biotin molecule (B, C). The peptides containing the biotinylated lysins appear to have a mass shift 
correspondent to the biotin molecule mass (B). In the sequence of SpeI shown above in bold are the peptides 
found in the MS analysis and in bold red the biotinylated lysins (C).
A B
C
3.3 Chip validation
Mouse and rabbit sera raised against the spotted recombinant proteins were used to verify 
the presence of the protein on the microarray and carry over of the protein in other spots. 
Serial dilution curves of Biotinylated Bovine Serum Albumine (BSA), Cy3/Cy5-labeled 
BSA, Mouse and Rabbit IgG are spotted in triplicates on the chip as controls for 
ﬂuorophore conjugated secondary antibodies and streptavidin and for the behavior of 
every pin on each printed slide during the spotting session.
Among the 93 proteins selected for this screening 4 are well know Fibronectin Binding 
Proteins. These were used as positive controls for validating both the printed microarrays 
and the experimental conditions used in the screening for protein-protein interactions.
Human ﬁbronectin was biotinylated under non-saturating conditions and it was 
incubated with the GAS proteins printed on the chip following the screening protocols. 
Binding was detected only for the spots of the ﬁbronectin binding proteins (Figure 3.3). 
The binding detection technique did not generate any false positive signal due to the 
conjugated streptavidin or the chip saturation. 
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Figure 3.3. Fibronectin binding proteins spots ﬂuorescence signal after hybridization with human ﬁbronectin. The for 
proteins present on the chip are: gi-19224141 (1), M6_Spy0157 (2), SpyM3_0104 (3) and gi-19224134 (4). It is 
also possible to notice the absence of any protein carry other to other spots and any other nonspeciﬁc binding caused 
by the detection system.
3.4 Protein-protein interactions
Considering the chip validation results criteria were determined for positive interaction 
results determination. First the ﬂuorescence value for positive binding was set, in a scale 
from 0 to 65000, to 5000 corresponding to the mean ﬂuorescence value of the negative 
control spots plus 3 times the standard deviation value. In addition, only reciprocal 
interactions, i.e. binding of the same two interactors irrespective of which of the two 
partners was immobilized on the chip or in solution, were taken as bona ﬁde protein-
protein interactions as schematized in Figure 3.4.
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Figure 3.4. Explanatory reciprocal interaction diagram. The proteins found to be 
reciprocally interacting are highlighted through parallel lines.
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Using these criteria, 25 reciprocal interaction have been identiﬁed, 20 of them regarding 
Streptococcal Pyrogenic Exotoxin I (SpeI), that belongs to the superantigen protein 
family secreted by GAS (Figure 3.5).
Among the SpeI interactors, 8 proteins are annotated as “hypothetical”. This shows the 
potential of this type of approach for characterization of proteins of unknown functions. 
The other SpeI interactors mostly pertain to the molecular chaperone proteins family 
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Figure 3.5. Results of the protein-protein interaction screening. All the binding detections are shown 
in this ﬁgure. Yellow squares correspond to a ﬂuorescence intensity signal from 5000 to 10000. Red 
squares stand for a signal of 10000 and above. Reciprocal interactions are highlighted by parallels lines.
Spotted GAS proteins
Bi
ot
in
yla
te
d 
G
AS
 p
ro
te
in
s 
us
ed
 a
s 
ov
er
la
y
dedicated to folding and thus probably involved in maturation and secretion of the 
superantigen. 
SpeI is know to dimerize forming a disulﬁde bond between two of the monomeric form 
of the protein that carry one single cysteine in its sequence. It has also been shown to 
have a monomer-dimer concentration dependant equilibrium (Brouillard, Gunther et al. 
2007). This observation was conﬁrmed by this approach and SpeI was found to interact 
with itself. When coming to “self ” interaction detection, it was not possible for obvious 
reasons to apply the reciprocal interaction rule, but SpeI was also found interacting with 
SPyl558 (TlpA) a protein disulﬁde reductase and SPy0925, a putative oxidoreductase as 
another conﬁrmation for this sort of behavior.  
SpeG was another protein found to be reciprocally interacting with SpeI. It’s a group IV 
SAg as SpeC and SpeJ (whereas SpeI belongs to group V), also present in the microarray, 
and it is described in the literature as capable of forming concentration-dependent 
homodimers (Proft, Moﬀatt et al. 1999; Sachse, Seidel et al. 2002). In this case the 
interaction between the two SAgs may suggest the formation of heterodimers.
SpeI has been shown to bind MHC-II molecules in a zinc-dependent manner (Proft, 
Arcus et al. 2001) and in this screening was found interacting with AdcA and Lmb, 
which belong to the transition metals transporter family. In particular AdcA is an 
orthologue of ZnuA: the substrate binding protein of the high aﬃnity zinc uptake system 
and Lmb is part of another transition metal transporter but with a general aﬃnity for 
Mn2+, Fe and, interestingly, Zn2+ (Desrosiers, Sun et al. 2007).
Figure 3.6 and Table 3.2 show the network of reciprocal interactions and annotation of 
the proteins. 
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Table 3.2. Annotation of proteins reciprocally interacting proteins.
SPy number Protein name Annotation
M5005_ SPy0249 OppA oligopeptidepermease
SPy0130  hypothetical protein
SPy0212 SpeG exotoxin G precursor 
SPy0317  hypothetical protein
SPy0604  hypothetical protein
SPy0714 AdcA Zinc-binding protein adcA/ putative 
adhesion protein
SPy0793  hypothetical protein
SPy0838  hypothetical protein
SPy0857 Mur1.2 putative peptidoglycan hydrolase
SPy0925  putative oxidoreductase
SPy1007 SpeI streptococcal exotoxin I
SPy1032 HylA Extracellular hyaluronate lyase
SPy1037  hypothetical protein
SPy1054  putative collagen-like protein
SPy1228  putative lipoprotein
SPy1326  hypothetical protein
SPy1520 FtsZ cell division protein
SPy1558 TlpAa Thioredoxinb
SPy1743 AccA acetyl-CoA carboxylase alpha subunit
SPy2000 DppA Dipeptide-binding protein 
SPy2007 Lmb putative laminin adhesion
SPy2037 PrsA peptidylprolyl isomerase Foldase protein prsA
SPy2066  putative dipeptidase
a (Koski, Saarilahti et al. 1992)
b (Lei, Liu et al. 2004)
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Figure 3.6. Reciprocal interaction network
3.5 Characterizing interactions by SPR 
Surface Plasmon Resonance: the Biacore Technology
Biacore® T100 is a system for comprehensive protein interaction analysis (Figure 3.7). It 
allows to measure kinetic rate constants over the broadest range, from the fastest on-rates 
to the slowest oﬀ-rates, to compare buﬀer eﬀects in a single run, to work with low 
molecular weight compounds and, particularly, to study interactions at physiological 
temperatures and above.
It is based on Surface Plasmon Resonance (SPR). The SPR is a physical phenomenon 
occurring when monochromatic polarized light hits a metal ﬁlm under total internal 
reﬂection conditions. Incident photons are adsorbed and converted in plasmons thus 
creating a gap in the intensity of reﬂected light at a particular angle (resonance angle). 
These dips of light related to change in resonance angle are detected by the instrument.
Figure 3.7. The Biacore T100.
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The core of Biacore T100 is the sensor chip (Figure 3.8). A dextran matrix covering a 
golden layer on a glass chip. It enables molecules to be immobilized to a sensor surface 
and provides a hydrophilic environment for interactions.
When screening for interactions the analyte is injected over the immobilized ligand and, 
whenever an interaction occurs, the change in mass on the sensor chip surface causes a 
change in resonance angle proportional to the amount of bound analyte. The resulting 
sensorgram (Figure 3.9) is the real time analysis of the biomolecular interactions and 
provides kinetics values for association and dissociation.
Figure 3.8. The Sensor Chip.
Figure 3.9. Surface Plasmon Resonance analysis of interactions.
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Analysis of interactions
Biacore technology was chosen as the methodology for verifying interactions found in the 
protein microarray screening as a solid technique for protein-protein interaction analysis 
(Onell and Andersson 2005). Among the most signiﬁcant interactions, 14 were selected 
to be analyzed on Biacore T100.
For this analysis the tagless form of the proteins were used in place of the His-tagged ones 
spotted on the microarray. This was done to verify also an eventual role of the Histidine 
tag in the interaction, especially when dealing with interaction involving metal binding 
proteins. Moreover the carboxymethilated dextran matrix of the sensor chip used was 
much more ﬂexible than the nitrocellulose coating of the microarray slides.
Ligand protein were immobilized by amine coupling and interactions were tested in the 
presence or absence of Zn2+.
All the selected interactions obtained using the microarray approach were conﬁrmed and 
veriﬁed with the biacore analysis. Dissociation kinetics were calculated by the instrument 
and koﬀ values (dissociation rates) were obtained in a range typical of stable binders (from 
1.4 x 10-4 to 3.9 x 10-3 s-1) and are reported in Table 3.3.
The interaction between SpeI and the two transition metal binding proteins was of 
particular interest and a more in-depth analysis was performed focusing on the 
interaction of the SAg in a zinc-dependent manner (Figure 3.10).
Biacore sensorgrams of these interactions demonstrate a stable binding between the 
proteins in presence of zinc ions whereas the interactions were not observed in the 
presence of EDTA. Aﬃnity constants (KD) were obtained for these interactions (Table 
3.4) showing AdcA interacting with SpeI with the highest aﬃnity (KD = 3.3 nM) when in 
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solution, greater than that observed for SpeI with itself (KD = 18 nM). Moreover, when in 
solution, SpeI interacted with AdcA and Lmb with similar aﬃnity (KD = 8 and 7 nM 
respectively). 
Sub-nanomolar dissociation constants as a result of non-covalent binding interactions 
between two molecules are rare. Nevertheless, there are some important exceptions. 
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Table 3.3. koﬀ obtained by Surface Plasmon Resonance analysis of selected interactions. 
Depending on the proteins selected to be immobilized on the sensor chip in two cases it was 
possible to calculate the KOFF of the reciprocal interaction as it was done on the microarray.
 In solution  Immobilized
koff (s-1)   
(10-4) 
koff (s-1) 
 (10-4) 

SpeG SpeI 8.2

AdcA SpeI 18.0 8.1 
SPy_1054 SpeI 2.8 
SPy_1054 Lmb 2.0 
DppA SpeI 4.5 
DppA Lmb 1.4 
Lmb SpeI 35.0 7.4 
SPy_2066 SpeI 3.4 
SPy_1326 SpeI 2.7 
SPy_0925 SpeI 2.0 
 


SpeG Lmb 8.7 
SPy_2066 Lmb 3.2 
SpeI SpeI 10.0 
Lmb Lmb 38.7 

     
R
ec
ip
ro
ca
l
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ra
l
Biotin and avidin bind with a dissociation constant of roughly 10-15 M (0.000001 nM) 
(Livnah, Bayer et al. 1993) and Ribonuclease inhibitor proteins may also bind to 
ribonuclease with a similar 10-15 M aﬃnity (Johnson, McCoy et al. 2007). It has to be 
kept in mind that the dissociation constant for a particular ligand-protein interaction, 
and in this case for protein-protein interaction, can change signiﬁcantly with 
experimental conditions (e.g. temperature, pH and salt concentration). The eﬀect of 
diﬀerent solution conditions is to eﬀectively modify the strength of any intermolecular 
interactions holding a particular ligand-protein complex together.
In pharmaceutical research aimed at drug production it is known that harmful side eﬀects 
can occur through drug molecules interactions with proteins for which they were not 
meant to or designed to interact with. Therefore research is aimed at designing drugs that 
bind to only their target proteins with high aﬃnity, typically from 0.1 to 10 nM which is 
mostly within the range observed for the analyzed interactions. In addition, the SpeI 
dimer formation aﬃnity value observed in the Biacore T100 analysis is the same as the 
Table 3.4. For the most interesting interactions a more in-depth analysis was performed on 
biacore T100 and KD values obtained are in the same range of those of Ras-GTP and RafRBD 
interaction (Nassar, Horn et al. 1996).
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one of Ras-GTP interacting with RafRBD: a reference value for protein-protein 
interactions (Nassar, Horn et al. 1996).
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Figure 3.10. Sensorgrams of the zinc dependent interaction of SpeI with the two 
transition metal transporter AdcA and Lmb with respectively high and low aﬃnity 
for zinc. e interaction is dependent on the concentration of the injected protein 
and it is not verified in presence of EDTA.
3.6 Sequence analysis of SpeI interactors
As part of a more accurate analysis of SpeI interactors the aminoacid sequence was 
compared between SpeI interacting and non-interacting proteins. 
The analysis was done on the basis of the single aminoacids as well as the amino acid 
groups frequency to verify if a particular aminoacid or a speciﬁc aminoacid group was 
playing a role in the interaction with the superantigen.
As Figure 3.11 shows, the pattern of aminoacid and aminoacid group frequencies of the 
interacting proteins is similar to the frequencies found for the microarray proteins that do 
not interact with SpeI.
The relative frequency of each aminoacid or aminoacid group was also analyzed leading 
to the same conclusions. 
Whereas a diﬀerent aminoacid variability does not suggest any particular conclusion 
regarding the analyzed proteins, a very similar variability suggests that they carry the same 
properties as all the other proteins and actually the same as the average GAS surface 
protein.
As shown in Figure 3.12, there is not a signiﬁcant diﬀerence in aminoacid composition 
among SpeI interactors when compared to the other spotted proteins.
This suggests a more speciﬁc interaction with the superantigen not dependent simply on 
sequence composition, but, perhaps, on a deﬁned binding site pertaining to a speciﬁc 
function.
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Figure 3.11. Sequence analysis of the SpeI interactors (B) compared to the other GAS proteins 
(A) present on the microarray. The sequence percentage of the single aminoacids or the 
percentage of a speciﬁc aminoacid group is comparable among the two groups.
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Figure 3.12. Sequence analysis of the SpeI interactors compared to the other GAS proteins present on the 
microarray. e standard deviation of sequence percentage of the single aminoacids and of the percentage 
of a specific aminoacid group is comparable among the two groups.
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3.7 Fluorescence analysis
Interesting results were obtained from the ﬂuorescence analysis of spotted controls. As 
mentioned before diﬀerent forms of BSA were present on the microarray as 8 points of 
serial dilutions starting from a concentration of 1 mg/ml or 0.5 mg/ml reaching 0.008 
mg/ml or 0.004 mg/ml.
In the case of the biotinylated BSA, used as a positive control for binding detection, the 8 
point serial dilutions ranged from 1 mg/ml to 0.008 mg/ml resulting in about 0.66 ng of 
protein in the highest concentration spot and about 0.012 ng in the lowest concentration 
spot. The ﬂuorescence value of the biotinylated BSA spots obtained by subtracting the 
background value was analyzed in every experiment and the mean showed below in 
Figure 3.13.
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Figure 3.13. Mean ﬂuorescence value of the biotinylated BSA curve of all the slides analyzed for 
this screening. The curve was spotted in triplicate on every slides since eventually spots with clear 
spotting anomalies are normally ﬂagged out during ﬂuorescence analysis. Very low standard 
deviation is observed on every spot.
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The ﬁrst ﬂuorescence value above 5000 (the cutoﬀ used in this screening) is the third 
point of the curve corresponding to 0.048 ng of biotinylated BSA on the spot. This gives 
an idea of the sensitivity of this approach, which is able to detect very low amount of 
biotinylated protein.
Another interesting result is the analysis of the control of every experiment which 
corresponds to the mean ﬂuorescence value of every protein spot when incubated only 
with streptavidin-Cy3.
The values, shown below in Figure 3.14, never reach half of our cutoﬀ value for a positive 
result, which is set at 5000.
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Figure 3.14. Mean ﬂuorescence value of protein spots of all the slides analyzed for this screening when 
incubated with only streptavidin. One slide incubated only with streptavidin-Cy3 was included into 
every experiment as hybridization and spotting control. The proteins are spotted in quadruplicates 
onto every slide and signals with clear anomalies are ﬂagged out during ﬂuorescence analysis and 
excluded. Every ﬂuorescence signal detected is less than half our chosen cutoﬀ of 5000 (background 
ﬂuorescence intensity plus 3 times its standard deviation).
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It has already been mentioned how it was expected to observe a diﬀerent behavior for a 
spotted protein compared to its binding properties when the same protein is in solution. 
A comparative ﬂuorescence analysis was performed for all the interactions showing the 
reciprocal ﬂuorescence value when available (Figure 3.15).
It’s clear how in most of the cases the ﬂuorescence value of the interaction for a given 
protein is highest when the protein is in solution. This is due to the technique that has 
one of the two interacting proteins immobilized on a nitrocellulose matrix and, thus, far 
from being ﬂexible.
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Figure 3.15. Fluorescence analysis of all interactions. Fluorescence values of reciprocal interactions are also reported w
hen available. Th
e diﬀerence in ﬂuoresce intensity 
depending on w
hich of the tw
o interactors is im
m
obilized or in solution suggest that high or low
 binding aﬃ
nity can’t be determ
ined by this particular approach.
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4. Discussion
The screening of about 100 proteins of Group A Streptococcus described in this work is 
considered as a ﬁrst step into understanding the composition of protein complexes 
present on the bacterial cell surface. As of today, eﬀorts are made in studying the cell 
surface architecture and in developing more advanced tools for protein complexes analysis 
(Gavin, Bosche et al. 2002; Ho, Gruhler et al. 2002; Yu, Braun et al. 2008).
Knowing the exact composition of the surface of the bacteria and its organization would 
provide an invaluable tool for developing an eﬀective vaccine against the pathogen. 
Antigens that are part of a vaccine composition may exist as part of a complex in vivo on 
the bacterial surface. 
Focusing the immune response against a complex instead of a single protein will generate 
a more eﬀective protective antibody response and will avoid the elicitation of “junk” 
antibodies that occurs when immunizing with only one component of a whole protective 
protein complex (Figure 4.1).
A protein microarray based experimental approach for high-throughput protein-protein 
interaction screening was successfully set up involving high throughput protein 
expression and puriﬁcation and microarray hybridization under straightforward 
experimental conditions.
The technique was validated conﬁrming known interactions (such as ﬁbronectin and 
ﬁbronectin binding proteins or SpeI dimerization) and using Biacore T100 analysis that 
conﬁrmed all the 14 interaction tested. Nevertheless, even after successful conﬁrmations, 
this approach must still be considered a screening for protein-protein interactions, where 
false positives and false negatives have to be expected. Moreover the resulting interactions 
72
need to be veriﬁed using diﬀerent in vitro techniques and need to be assayed in vivo with 
other methodologies. Another limitation emerged regarding protein behavior, which can 
be very diﬀerent when the protein is immobilized or in solution. This would result in a 
unilateral interaction, instead of a reciprocal one, and become a false negative.
Even though a small number of proteins was included in this screening, interesting 
interactions emerged mostly regarding an important exotoxin of Group A Streptococcus 
probably unraveling the mechanism that leads to the maturation and activation of the 
protein with zinc ions (Proft, Moﬀatt et al. 1999; Arcus, Proft et al. 2000) via the 
interaction with two substrate binding proteins of the transition metal sABC transporter 
family (Chandra, Yogavel et al. 2007; Desrosiers, Sun et al. 2007).
Another interesting interaction of SpeI, conﬁrmed by Biacore analysis, is the one with 
DppA, another protein belonging to the ABC transporters family in this case speciﬁc for 
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Figure 4.1. Screening for surface protein complexes applied to vaccine research. Immunizing with a complex 
will avoid elicitation of junk antibodies and will elicit more functional ones.
1.  Avoid elicitation of “junk” antibodies
Protective antigen
Region at risk of 
generating “junk” antibodies
2. Use of antigens combos which naturally interact on the 
bacterial surface to elicit optimal protective antibody 
responses 
Functional antibody
Antigen used
for immunization
Antigens to be used to
elicit functional antibodies
the uptake of dipeptides (Podbielski and Leonard 1998). Podbielski and Leonard 
described also the inﬂuence of this protein on SpeB production, another superantigen 
with cysteine protease functions. This interaction supports the theory that many proteins 
participate in the maturation of superantigens during their secretion.
The ﬁnding of a unique domain for secretion in S. pyogenes, the ExPortal, and the 
knowledge that it contributes to the secretion of another SAg family protein (SpeB) 
(Rosch and Caparon 2005) suggest that a protein exported through this domain may 
have many interactions with other proteins secreted by the bacterium during its transport 
to the outside and maturation. As reported before, immobilization of the protein samples 
on solid supports has drawbacks. Possible distortion of the immobilized proteins as well 
as inconsistent orientation of spotted proteins on the arrays can lead to erroneous results 
(Washburn 2003). Recently, a new method adopting mass spectrometry techniques has 
been developed as an alternative to protein microarrays, but it is time consuming and can 
be used only for a small set of proteins (Ouyang, Takats et al. 2003).  Nevertheless, 
considering all the interactions found during this screening, both reciprocal and 
unilateral ones, it is possible to start to unravel the major interaction networks of S. 
pyogenes as part of a much broader picture. Even though in this study only reciprocal 
interactions have been taken into account, several interesting ones may be present in the 
univocal interactions that may be veriﬁed with diﬀerent approaches (Figure 4.2).
In conclusion it has been shown how protein microarrays could be used for high 
throughput screening of protein-protein interactions in vitro under straightforward 
experimental conditions, revealing several interactions and opening new perspectives on 
the current understanding of how proteins are modiﬁed by the bacterial cell in order to 
become major players in causing disease.
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Major interaction networks
75
Figure 4.2. Major interaction networks. Reciprocal interactions (in blue) and the unilateral interactions are shown 
resulting in a much broader picture regarding S. pyogenes surface protein complexes. 
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Appendix
Spotting program:
VersArray ChipWriter Pro system
Data ﬁle about Arraying run settings
Created: 01/11/08-10:48:28 
[Source Plate]
Source Plate Type(Number of Wells)= 384(24x16)
Number of Source Plate Positions= One
Sample Picking Direction= Top-down, Left-right
Barcode Reading= No
[Print Head]
Pin Type= Quill
Use Every Second Hole= No
Number of Pins in Y Axis= 2
Number of Pins in X Axis= 6
[Slide/Membrane]
S/M Mode= Slides
Number of Slides in Y= 16
Number of Slides in X= 4
Slide Size(X by Y)= 75x25
Number of Slides between Redips= 64
Dwell Time for Printing= 0.010 (Sec)
[Grid]
Top Left Grid Margin in X= 9.000 (mm)
Top Left Grid Margin in Y= 6.000 (mm)
Bottom Right Grid Margin in X= 2.000 (mm)
Bottom Right Grid Margin in Y= 9.000 (mm)
Distance between Dots in X= 260.000 (micron)
Distance between Dots in Y= 260.000 (micron)
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No. of Dots Per Grid in X= 10 
No. of Dots Per Grid in Y= 12 
No. of Duplicate Dots Per Grid in X= 1 
No. of Duplicate Dots Per Grid in Y= 1 
No. of Reprints of  the Same Dot= 1 
Grid Printing Direction= Left-right, Top-down 
No. of Diﬀerent Supergrids in X= 1 
No. of Diﬀerent Supergrids in Y= 1 
Distance between Supergrids in X= 4.500 (mm)
Distance between Supergrids in Y= 5.670 (mm)
Supergrid Printing Direction= Left-right, Top-down 
No. of Duplicate Supergrid Clusters in X= 1 
No. of Duplicate Supergrid Clusters in Y= 1 
Distance between Duplicate Supergrid Clusters in X= 4.500 (mm) 
Distance between Duplicate Supergrid Clusters in Y= 4.500 (mm) 
Use Full Plates= No 
No. of Full Plates= 3 
No. of Wells in Last Plate= 288 
Total No. of Spots in a Grid= 120 
[Stacker/Blot]
Use Stackers= Yes
Number of Stackers Used= 5
Use Lid Option= Each plate has lid
Total number of plates in stackers per loading cycle per stacker= 1
Use Blots= Yes
Number of blot slides in blot adapters BLOT1= 2
Number of blot slides in blot adapters BLOT2= 0
Number of blot slides in blot adapters BLOT3= 0
Number of blot slides in blot adapters LONG BLOT= 0
Number of blots per sample= 12
All blotting slides are suﬃcient for= 5 (plates)
[Washing]
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No. of Wash Cycles= 5
Wash Time Per Cycle= 3.000 (sec)
Vacuum Time= 1.000 (sec)
Last Vacuum Time= 2.500 (sec)
UltraSonic Clear Time= 12.000 (sec)
No. of Dips between Sonications= 1
No. of Wash Sessions between Water Bath Reﬁllings= 5
Water Bath Fill Time= 10.700 (sec)
Include Re-dips into No. of Dips(Sonication)= No
Oscillate Pins in Water= Yes
Wash Selection= Always Wash
[Options]
Source Plate Travel Time Down= 1.000 (Sec)
Source Plate Travel Time Up= 1.000 (Sec)
Source Plate Wait Time In= 1.500 (Sec)
Water-bath Oscillation Distance in X= 2.000 (mm)
Water-bath Number of Oscillations in Bath= 4
Blot Slides Blot Distance= 400 (micron)
Blot Slides Blot Dwell Time= 0.030 (sec) 
Slide/Membrane/Blot Approach Speed= 6.000 (mm/sec)
*********************************************************
Run Start:
Plate No.   FirstDip Time   Last Dip Time   Last Dip No.   Last Slide 
        1           10:51:15             12:27:06             32             (1,4)                     
        2           12:28:58             14:04:48             32             (1,4)
        3           14:06:39              15:42:29                 32                      (1,4)          
        4           15:44:21            16:57:41                 24             (1,4)                      
Run End
*********************************************************
83

Acknowledgments
Sergio
Mauro 
Luisa
Fabiana
Renata 
Barbara
Renzo
Nathalie 
Silvia
Cesira
Guido
Balloni
Bombaci 
Bracci*
Falugi
Grifantini 
Lelli* 
Nogarotto
Norais 
Pileri*
Galeotti
Grandi
*Department of Molecular Biology, University 
of Siena, Via Fiorentina 1, 53100, Siena, Italy
Giuliano
Alessandra
Sabrina
Emiliano
Giuliano
Marilena
Immaculada
Vincenzo
Salvatore
Simone
Roberto
Giacomo
Erwin
Vincenzo
Rino
Bensi
Blasiotti
Capo
Chiarot 
Galli
Gallotta
Margarit Y Ros
Nardi Dei
Nocadello
Pasquini
Petracca
Romagnoli
Swennen
Scarlato
Rappuoli
Novartis Vaccines, Siena and 
